

References

I-9020

1. Vyvgart Prescribing Information. Argenx US, Inc. December 2021.
2. National Institute of Neurological Disorders and Stroke. Myasthenia Gravis Fact Sheet. NIH Publication No. 17-768. July 2018.
3. Narayanaswami P, Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. 2020 Update. *Neurology* Volume 96; Number 3. January 19, 2021.
4. Ulrichs P, Guglietta A, Dreier T, et al. *J Clin Invest*. 2018;128(10):4372-4386.
5. Huijbers MG, Plomp JJ, van Es IE, et al. *Exp Neurol*. 2019;317:133-143.
6. Dhavalkumar DP, Bussel JB. Neonatal Fc receptor in human immunity Function and role in therapeutic intervention. *J Allergy Clin Immunol* 2020;146:467-78.
7. Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichs P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol*. 2021 Jul;20(7):526-536. doi:10.1016/S1474-4422(21)00159-9. PMID: 34146511.
8. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. *Autoimmune Dis*. 2012;2012:874680. doi:10.1155/2012/874680.
9. Bird SJ. UpToDate. Overview of the treatment of myasthenia gravis. Literature review current through January 2022.